Cheryl Eitman

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.

Christopher Hoimes, Nabil Adra, Mark T. Fleming et al. · Journal of Clinical Oncology · 2020 · 50 citations

Medicine, Oncology, Urology +17

Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.

Hristos Z. Kaimakliotis, Nabil Adra, William Kevin Kelly et al. · Journal of Clinical Oncology · 2020 · 43 citations

Medicine, Oncology, Urology +14

A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)

Christopher Hoimes, Costantine Albany, Jean Hoffman‐Censits et al. · Annals of Oncology · 2018 · 35 citations

Medicine, Oncology, Pharmacology +7

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer

Blaine Brower, Asia S. McCoy, Hiba Ahmad et al. · Frontiers in Oncology · 2024 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17